Treatment options--development of consensus guidelines. - Wikidata - awgldk - TriplyDB

Treatment options--development of consensus guidelines.

Treatment options--development of consensus guidelines.

http://www.wikidata.org/entity/Q33989540

about

Update on therapy for superficial mycoses: review article part I The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.Onychomycosis: modern diagnostic and treatment approaches.The Effect of Q-Switched Nd:YAG 1064 nm/532 nm Laser in the Treatment of Onychomycosis In Vivo.Management of Onychomycosis in Canada in 2014.Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment.An update on treatment of onychomycosis.Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis.Oral therapy for onychomycosis: an evidence-based review.Treatment of superficial mycoses: review. Part II Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.Toenail Onychomycosis-A Canadian Approach With a New Transungual Treatment: Development of a Clinical Pathway.Tavaborole - a treatment for onychomycosis of the toenails.Potential role of tavaborole for the treatment of onychomycosis.Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment.Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.Multicenter evaluation of a commercial PCR-enzyme-linked immunosorbent assay diagnostic kit (Onychodiag) for diagnosis of dermatophytic onychomycosis.Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double-blind, randomized, placebo-controlled multicenter study.Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.Onychomycosis: A Review.Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success.Antifungal activity of propolis extract against yeasts isolated from onychomycosis lesions.Efficacy of antifungal PACT in anin vitromodel of onychomycosis Case Study of Onychomycosis Patients Treated with 1,064-nm Nd:YAG Laser

P2860

Q24608381-7019360C-E5BF-4114-BFBF-ED09159D5575 Q33931289-D5D9AECE-B235-4603-A15D-5840E98E136F Q34440038-E10461CA-F780-4645-89C2-1FCB12C3890D Q35084282-30CDD0A8-CAA6-4DB2-A45A-0F51A6024502 Q35578703-ED86F436-0CB2-4F3C-972D-8DA10BD566B0 Q36412047-CB58C673-F050-4A6F-AC41-16E9CDA2E434 Q38006059-EEED29C2-6414-4C61-8E61-0B4519CDDD48 Q38033192-B1EBED86-D5EC-4826-9BD7-23646F0883E1 Q38172442-3B4C59DE-0D39-4FC1-8998-A16594249738 Q38182892-F09135E7-A722-4008-AF4A-B9D235DFB180 Q38217420-AF28D2B4-E763-4DA4-BE7A-4E5E32C03908 Q38395475-3DE231CD-A6E8-4B9F-AED6-F876E9886FBC Q38413107-C0F229B8-B3E4-4997-8432-9C562A966E98 Q38878252-FD400412-90E4-465E-865F-CA8A667B3595 Q39092182-4AD704C1-30D4-4C75-B349-9F8C9DA2164A Q39352777-C998DC5F-14D5-4A78-B718-645BB5CAB9A7 Q41019142-9C8A6E68-22BA-4DBE-83B3-342DDAB10A5E Q41826970-1A016CAC-E621-4662-AA1F-16BE244CCA4E Q45366391-535B790E-BFCE-47C0-8A60-580AB80CE467 Q46158200-11F6CE99-4ECB-481B-9FA5-F74122A3B7DE Q48149284-04B0BFF6-2BBF-4C4D-8DA7-1B8AB03EA0EE Q49476861-FBEEBDD2-BB20-4712-8203-BE8BC4BA1F34 Q52673783-607F0676-779C-4B41-A49C-94574FA81589 Q53747721-02FC76C2-9B51-4D0F-9D56-F040A0D8E975 Q57130288-9CAEE010-4832-42C0-819F-6309692AB7E4

P2860

Treatment options--development of consensus guidelines.

http://www.wikidata.org/entity/Q33989540

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Treatment options--development of consensus guidelines.

@ast

Treatment options--development of consensus guidelines.

@en

type

label

Treatment options--development of consensus guidelines.

@ast

Treatment options--development of consensus guidelines.

@en

prefLabel

Treatment options--development of consensus guidelines.

@ast

Treatment options--development of consensus guidelines.

@en

P1433

Q33989540-0342B400-397B-40D7-9E15-C439FE519183

P1476

Q33989540-A9F657FA-EAD5-47B3-A552-39E965F7CD68

P2093

Q33989540-0A2DA254-10A7-49B9-A27E-939DF69206BE

Q33989540-1D05AC5E-89A4-4BCF-8749-C82C64081E81

Q33989540-2E7E7369-7C64-4AE2-BCEF-A872E1C9C40A

Q33989540-2F69233A-307A-451F-87A8-AF8DF8157187

Q33989540-471B76E3-CC9C-41E2-8AF8-9ED455DF856E

Q33989540-D272849C-154F-4DEC-A720-01ED4D1E4A11

P2860

Q33989540-4DBCFEDC-990B-414D-883B-AA6F0B03877B

Q33989540-54F73ED6-1EC9-405A-BEE3-B75A33DB6362

Q33989540-8417891E-83EA-487E-AD94-145FC9A95624

Q33989540-9A5A1D55-98F2-49EA-B589-A24D8BDE27E8

Q33989540-B22E7039-944D-47C5-B1CF-94962BC397D5

Q33989540-B39F166C-9100-4D18-9838-8D8837D59924

Q33989540-D9532107-82DB-41A6-9026-5A12A8BF9C03

Q33989540-E07463FF-AF6A-46A9-85B7-AE93F0435B02

Q33989540-E4D35D10-B33F-45D7-8D38-D6777FCCAA19

Q33989540-F8CD494B-8DF0-4778-85D3-9CE35D1EBA13

P304

Q33989540-DCD1D5FB-425E-41AC-9329-842D37181ED8

P31

Q33989540-68F0299D-DAF8-4422-A420-887CA557EE33

P356

Q33989540-8195B6EB-0468-4FCF-852E-33FADF2DBC87

P478

Q33989540-67C1C899-386C-4729-8285-F74F7FA2B824

P577

Q33989540-916ED58B-C113-4407-AF20-72DB52C8B470

P5875

Q33989540-565BFEC9-8FAE-491A-91A7-5BCF4F3F8574

P698

Q33989540-A8267A11-AE83-4BFC-87BC-3CCA103F6B26

P356

J.1468-3083.2005.01284.X

P1433

Journal of the European Academy of Dermatology and Venereology

P1476

Treatment options--development of consensus guidelines.

@en

P2093

I Effendy

http://www.w3.org/2001/XMLSchema#string

M Feuilhade de Chauvin

http://www.w3.org/2001/XMLSchema#string

M Lecha

http://www.w3.org/2001/XMLSchema#string

N Di Chiacchio

http://www.w3.org/2001/XMLSchema#string

R Baran

http://www.w3.org/2001/XMLSchema#string

Taskforce on Onychomycosis Education

http://www.w3.org/2001/XMLSchema#string

P2860

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data.

The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine.

A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.

Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.

Ciclopirox: an overview.

Onychomycosis: strategies to improve efficacy and reduce recurrence.

Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis.

Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.

Testing of antifungal combinations against yeasts and dermatophytes.

P304

25-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-3083.2005.01284.X

http://www.w3.org/2001/XMLSchema#string

P478

19 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7640899

http://www.w3.org/2001/XMLSchema#string

P698

16120203

http://www.w3.org/2001/XMLSchema#string